Descripción del proyecto
Ejercicio contra la astenia por cáncer de mama
La tasa de diagnóstico precoz y tratamiento del cáncer de mama ha mejorado considerablemente a lo largo de los años. Sin embargo, hasta un 40 % de las pacientes desarrollan metástasis. Nuevas mejoras en el tratamiento del cáncer de mama metastásico (CMM) han logrado alargar la vida de las pacientes. Sin embargo, las pacientes con CMM sufren efectos secundarios dañinos como astenia, dolor, náuseas y vómitos, insomnio, disnea y disfunción emocional, social y cognitiva. El efecto secundario más habitual relacionado con el tratamiento es la astenia, que repercute negativamente en la calidad de vida de las pacientes. El proyecto financiado con fondos europeos PREFERABLE contribuirá a mejorar el tratamiento del CMM aumentando la calidad de vida. El proyecto utilizará una intervención no farmacológica, que combina ejercicio supervisado y no supervisado basado en una aplicación que aportará pruebas de su efecto beneficioso sobre los efectos secundarios del CMM.
Objetivo
Despite the tremendous improvement in early diagnosis and treatment of breast cancer, a large proportion (up to 40%) of patients with breast cancer will eventually develop metastases. Patients with metastatic breast cancer (MBC) have a median overall survival of 2-3 years, and a relative 5-year survival of 34%. Current advances in therapy have extended the life of those patients with MBC, however these patients still suffer (for longer periods) from deleterious side-effects (either related to the disease itself or to the treatment) such as fatigue, pain, nausea and vomiting, insomnia, dyspnoea, emotional, social and cognitive dysfunction. Among all these side-effects, fatigue is the most common and distressing treatment-related side-effect, as up to 90% of patients with MBC experience fatigue over the course of treatment. All these symptoms negatively affect patients’ QoL and thus an urgent solution is needed to help those with advanced breast cancer to “live well” for as long as possible.
PREFERABLE’s vision is to improve the standard of care in MBC by improving the quality, effectiveness and cost-effectiveness for patients in a palliative setting using a non-pharmacological intervention combining supervised and unsupervised app-based exercise. Based on the results from a multinational randomised controlled phase 3 clinical trial (EFFECT trial; (cost)- effectiveness study), the different perspectives of patients with MBC on exercising (PERSPECTIVE study), and through mapping the differences in the European healthcare systems, the PREFERABLE project will generate solid and conclusive evidence of the beneficial effect of exercise on cancer-related side effects and patients’ quality of life in the palliative setting. By this, PREFERABLE will contribute towards reshaping medical practice and improving clinical guidelines and recommendations.
Ámbito científico
Palabras clave
Programa(s)
Convocatoria de propuestas
Consulte otros proyectos de esta convocatoriaConvocatoria de subcontratación
H2020-SC1-2018-Single-Stage-RTD
Régimen de financiación
RIA - Research and Innovation actionCoordinador
3584 CX Utrecht
Países Bajos